Latest news with #MasoudToloue
Yahoo
4 days ago
- Business
- Yahoo
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass., June 06, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. View source version on Contacts Media Contact: Marissa Klaassenmedia@ Investor Relations Contact: Joshua Youngir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 days ago
- Business
- Business Wire
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46 th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9 th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa ® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn.
Business Wire
12-05-2025
- Business
- Business Wire
Quanterix Releases Financial Results for the First Quarter of 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward,' said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by a breakthrough in reagent design: Simoa's digital, ultra-sensitive detection now operates with kinetic dye-encoded beads, dramatically expanding our reach to an installed base more than twenty times the size of our own. We are democratizing access to ultrasensitive biomarker detection by meeting researchers where they are—a major step forward in our mission to bring Simoa to all labs." Toloue continued, "Following a solid first quarter that exceeded our expectations, we are proactively positioning the company for long-term success. In light of ongoing market headwinds, we are taking a disciplined approach to guidance and implementing targeted cost reductions of approximately $30 million annually. These actions strengthen our path to generate positive cash flow by 2026, reinforce our commitment to sustainable innovation-driven growth, and help to streamline our coming integration with Akoya Biosciences." First Quarter Financial Highlights Revenue of $30.3 million, a decrease of 5% compared to $32.1 million in the prior year. GAAP gross margin of 54.1%, as compared to 57.8% in the prior year. Adjusted gross margin (non-GAAP) of 49.7% as compared to 51.2% in the prior year. Net loss of $20.5 million, compared to a net loss of $11.2 million in the prior year. The Company ended the first quarter with $269.5 million of cash, cash equivalents, marketable securities, and restricted cash, representing a use of cash of approximately $22 million. During the quarter, Quanterix incurred $13.2 million of cash expenses relating to the EMISSION acquisition, Akoya deal expenses and the Company's previous restatement. Excluding these payments, adjusted cash burn in the quarter was $9.0 million, compared to adjusted cash burn of $19.4 million in the prior year. Operational and Business Highlights ARUP Laboratories, a leading national reference laboratory in the United States announced they will now offer a pTau217 blood test for Alzheimer's disease using the Quanterix platform and assay kit. Received Proprietary Laboratory Analysis (PLA) codes for LucentAD® and LucentAD Complete tests, with pricing expected in the third quarter of 2025. Launched a new dried blood spot (DBS) extraction kit, expanding the Simoa assay portfolio with a less invasive, more cost-effective method for detecting low-abundance biomarkers- expanding access to high-sensitivity testing in a broader range of settings Amended the merger agreement with Akoya Biosciences, reducing the equity value of the transaction by 67% and increasing Quanterix shareholder ownership from 70% to 84% post-closing. The transaction is expected to close in June 2025. Implementing cost reduction initiatives to achieve $30 million in annual savings. This is a first step toward generating positive cash flow by 2026 with a cash balance in excess of $100 million. 2025 Full Year Business Outlook In assessing recent cuts to academic research funding, biopharma spending patterns, and tariffs, for 2025, on a standalone basis excluding the planned acquisition of Akoya, the Company expects to report revenues in a range of $120 million to $130 million, which represents a year-over-year revenue decline of 5% to 13%. This estimate excludes revenue from Lucent Diagnostics testing. The Company expects GAAP gross margin to be in the range of 55% to 59%, and adjusted gross margin (non-GAAP) in the range of 50% to 54%. Finally, the Company anticipates 2025 adjusted cash burn to be approximately $35.0 million to $45.0 million. For additional information on the non-GAAP financial measures included in this press release, please see 'Use of Non-GAAP Financial Measures' and 'Reconciliation of GAAP to Non-GAAP Financial Measures' below. Conference Call In conjunction with this announcement, the Company will host a conference call on May 12, 2025, at 4:30 PM E.T. The dial-in number for USA & Canada is Toll-Free (800) 715-9871 or (646) 307-1963 and the conference ID is 7353673. Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at An archived webcast replay will be available on the Company's website for one year. Financial Highlights QUANTERIX CORPORATION CONSOLIDATED BALANCE SHEETS (amounts in thousands, except per share data) December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 76,508 $ 56,709 Marketable securities 190,369 $ 232,413 Accounts receivable, net of allowance for expected credit losses 28,258 $ 32,141 Inventory 31,028 $ 32,775 Prepaid expenses and other current assets 8,839 $ 9,556 Total current assets 335,002 363,594 Restricted cash 2,639 $ 2,610 Property and equipment, net 16,457 $ 17,150 Intangible assets, net 16,520 $ 4,031 Goodwill 6,574 $ — Operating lease right-of-use assets 15,971 $ 16,339 Other non-current assets 3,349 $ 2,809 Total assets $ 396,512 $ 406,533 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 6,731 $ 6,953 Accrued compensation and benefits 6,308 $ 12,620 Accrued expenses and other current liabilities 13,314 $ 8,851 Deferred revenue 9,102 $ 8,827 Operating lease liabilities 4,940 $ 4,756 Total current liabilities 40,395 42,007 Deferred revenue, net of current portion 1,098 $ 1,073 Operating lease liabilities, net of current portion 31,467 $ 32,615 Non-current portion of contingent consideration 6,337 $ — Other non-current liabilities 822 $ 800 Total liabilities 80,119 76,495 Total stockholders' equity 316,393 330,038 Total liabilities and stockholders' equity $ 396,512 $ 406,533 Expand QUANTERIX CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (amounts in thousands) Three Months Ended March 31, 2025 2024 Cash flows from operating activities: Net loss $ (20,504 ) $ (11,163 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense 2,188 $ 1,523 Credit losses on accounts receivable 53 $ 73 Accretion of marketable securities (979 ) (1,657 ) Operating lease right-of-use asset amortization 561 478 Stock-based compensation expense 5,462 5,265 Change in fair value of contingent consideration 379 — Other operating activity (412 ) 55 Changes in assets and liabilities: Accounts receivable 4,329 (4,130 ) Inventory 2,085 (2,531 ) Prepaid expenses and other current assets 421 (281 ) Other non-current assets (502 ) (33 ) Accounts payable 399 (1,057 ) Accrued compensation and benefits, accrued expenses, and other current liabilities (3,517 ) (6,200 ) Deferred revenue 299 472 Operating lease liabilities (1,157 ) (988 ) Other non-current liabilities (2,993 ) 10 Net cash used in operating activities (13,888 ) (20,164 ) Cash flows from investing activities: Purchases of marketable securities (30,246 ) (137,889 ) Proceeds from sales and maturities of marketable securities 73,261 29,200 Purchases of property and equipment (1,256 ) (506 ) Acquisition, net of cash acquired (8,997 ) — Net cash provided by (used in) investing activities 32,762 (109,195 ) Cash flows from financing activities: Proceeds from common stock issued under stock plans 668 2,037 Payments for employee taxes withheld on stock-based compensation awards (575 ) (1,438 ) Net cash provided by financing activities 93 599 Net increase (decrease) in cash, cash equivalents, and restricted cash 18,967 (128,760 ) Effect of exchange rate changes on cash, cash equivalents, and restricted cash 861 (380 ) Cash, cash equivalents, and restricted cash at beginning of period 59,319 177,026 Cash, cash equivalents, and restricted cash at end of period $ 79,147 $ 47,886 Expand Use of Non-GAAP Financial Measures To supplement our financial statements presented on a U.S. GAAP basis, we present the following non-GAAP financial measures: Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income (loss) adjusted to exclude interest income, income tax (expense) benefit, depreciation and amortization expense, stock-based compensation expense, acquisition and integration related costs, impairment and restructuring, and certain other items which include other charges or benefits resulting from transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. These items are discussed in more detail below the tables reconciling the GAAP to non-GAAP measures. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenues. Adjusted gross profit, adjusted gross margin, adjusted total operating expenses, and adjusted loss from operations: We calculate these non-GAAP financial measures by including shipping and handling costs for product sales within cost of product revenue instead of within selling, general and administrative expenses. Additionally, we exclude amortization of certain acquired intangible assets, acquisition and integration related costs, and certain other items which include other charges or benefits resulting from transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues. Adjusted cash burn: We calculate cash burn as the total change in cash, cash equivalents, and restricted cash adjusted to include the net change from purchases, sales, and maturities of marketable securities (excluding any interest receivable). Adjusted cash burn is calculated as cash burn further adjusted to exclude cash payments related to transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. We believe that presentation of these non-GAAP financial measures provides supplemental information useful to investors in understanding our underlying operating results and trends. We use these non-GAAP financial measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. We believe that presentation of these non-GAAP financial measures provides useful information to investors in assessing our operating performance within our industry and to allow comparability with the presentation of other companies in our industry. The non-GAAP financial measures presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with U.S. GAAP. For example, adjusted EBITDA excludes a number of expense items that are included in net loss and adjusted cash burn excludes certain actual cash payments. As a result, positive adjusted EBITDA or positive adjusted cash burn may be achieved even where we record a significant net loss or reduction in our cash and marketable securities balances in accordance with U.S. GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned 'Reconciliation of GAAP to Non-GAAP Financial Measures' in the section below. Additionally, we make certain forward-looking statements about our future financial performance that include non-GAAP financial measures, which are difficult to predict for future periods because the nature of the adjustments pertains to events that have not yet occurred. We do not forecast many of the excluded items for internal use and therefore information reconciling forward-looking non-GAAP financial measures to U.S. GAAP financial measures is not available without unreasonable effort and is not provided. The occurrence, timing, and amount of any of the items excluded from U.S. GAAP to calculate non-GAAP financial measures could significantly impact our U.S. GAAP results. (1) Represents acquisition and integration costs directly related to the Company's business combinations. Acquisition costs include professional and consulting fees supporting due diligence, legal, and accounting activities to execute a transaction. Integration costs include third party and internal direct costs to integrate acquired companies, employees, and their customers. (2) Consists of the earnout recognized as compensation expense related to the Emission acquisition. (3) Consists of fair value adjustments for the contingent consideration liability related to the Emission acquisition. Expand (1) Represents cash payments towards acquisition and integration related activities, including the purchase of a business (net of cash acquired). (2) Payment of costs associated with the restatement of previously issued financial statements that was completed at the end of 2024. Expand QUANTERIX CORPORATION Reconciliation of Gross Profit, Gross Margin, Total Operating Expenses and Loss from Operations to Non-GAAP Financial Measures (Unaudited, amounts in thousands except percentages) Three Months Ended March 31, 2025 2024 Gross profit $ 16,415 $ 18,548 Shipping and handling costs (1,577 ) (2,142 ) Amortization of acquired intangible assets (1) 227 — Adjusted gross profit (non-GAAP) $ 15,065 $ 16,406 Total revenues $ 30,333 $ 32,066 Gross margin (gross profit as % of total revenues) 54.1 % 57.8 % Adjusted gross margin (non-GAAP) (adjusted gross profit as % of total revenues) 49.7 % 51.2 % Total operating expenses $ 42,781 $ 33,705 Shipping and handling costs (1,577 ) (2,142 ) Acquisition and integration related costs (2) (3,578 ) — Earnout recorded as compensation expense (3) (3,744 ) — Adjusted total operating expenses (non-GAAP) $ 33,882 $ 31,563 Loss from operations $ (26,366 ) $ (15,157 ) Amortization of acquired intangible assets (1) 227 — Acquisition and integration related costs (2) 3,578 — Earnout recorded as compensation expense (3) 3,744 — Adjusted loss from operations (non-GAAP) $ (18,817 ) $ (15,157 ) Expand (1) Consists only of the amortization of intangible assets acquired in 2025. (2) Represents acquisition and integration costs directly related to the Company's business combinations. Acquisition costs include professional and consulting fees supporting due diligence, legal, and accounting activities to execute a transaction. Integration costs include third party and internal direct costs to integrate acquired companies, employees, and their customers. (3) Consists of the earnout recognized as compensation expense related to the Emission acquisition. Expand About Quanterix From discovery to diagnostics, Quanterix's ultra-sensitive biomarker detection is driving breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. ('Akoya') by Quanterix (the 'Merger'), Quanterix will file with the U.S. Securities and Exchange Commission (the 'SEC') a post-effective amendment to its registration statement on Form S-4 (as amended, the 'Registration Statement'), which will contain a preliminary proxy statement of Akoya and a preliminary prospectus of Quanterix (the 'Proxy Statement/Prospectus'), and each of Quanterix and Akoya have, and may in the future, file with the SEC other relevant documents regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT QUANTERIX, AKOYA AND THE PROPOSED TRANSACTION. A definitive copy of the Proxy Statement/Prospectus will be mailed to Akoya stockholders when that document is final. Investors and security holders will be able to obtain the Registration Statement and the Proxy Statement/Prospectus, as well as other filings containing information about Quanterix and Akoya, free of charge from Quanterix or Akoya or from the SEC's website when they are filed. The documents filed by Quanterix with the SEC may be obtained free of charge at Quanterix's website, at or by requesting them by mail at Quanterix Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821. The documents filed by Akoya with the SEC may be obtained free of charge at Akoya's website, at or by requesting them by mail at Akoya Biosciences, Inc., 100 Campus Drive, 6th Floor, Marlborough, MA 01752, ATTN: Chief Legal Officer. PARTICIPANTS IN THE SOLICITATION Quanterix and Akoya and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Akoya in respect of the proposed transaction. Information about Akoya's directors and executive officers is available in the Proxy Statement/Prospectus and Amendment No. 1 to Akoya's Annual Report on Form 10-K as filed with the SEC by Akoya on April 28, 2025, and other documents filed by Akoya with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Investors should read the definitive Proxy Statement/Prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Quanterix or Akoya as indicated above. NO OFFER OR SOLICITATION This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the Merger, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this press release which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix's future business outlook, operations, strategy and financial performance, including statements under the header '2025 Full Year Business Outlook,' and statements about the Merger. Words and phrases such as 'may,' 'approximately,' 'continue,' 'should,' 'expects,' 'projects,' 'anticipates,' 'is likely,' 'look ahead,' 'look forward,' 'believes,' 'will,' 'intends,' 'estimates,' 'strategy,' 'plan,' 'could,' 'potential,' 'possible' and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix's future business, operations, strategy and financial performance: risks related to the impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs; risks that we may not realize the expected benefits of our cost reduction actions; risks associated with the anticipated timing for launch of, and features of, Quanterix's next-generation instrument, Simoa ONE; risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisition of Emission, Inc.; that Quanterix's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to the restatement of Quanterix's consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation; risks related to Quanterix's ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation; Quanterix's ability to realize the intended benefits of its assay redevelopment program; and Quanterix's ability to retain and expand its customer base and achieve sufficient market acceptance of its products. Such risks and uncertainties include, among others, the following possibilities with respect to the Merger: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the merger agreement between Quanterix and Akoya; the outcome of any legal proceedings that may be instituted against Quanterix or Akoya; the failure to obtain necessary Akoya stockholder approval or to satisfy any of the other conditions to the Merger on a timely basis or at all; the possibility that the anticipated benefits and synergies of the Merger are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business; the possibility that the Merger may be more expensive to complete than anticipated; diversion of management's attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger; changes in Quanterix's share price before the closing of the Merger; risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the Merger; and other factors that may affect future results of Quanterix, Akoya and the combined company. Additional factors that could cause results to differ materially from those described above can be found in the Proxy Statement/Prospectus, and in periodic reports filed by Quanterix and Akoya with the SEC, including the 'Risk Factors' sections contained therein, which are available on the SEC's website at All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix's or Akoya's underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix and Akoya anticipate. Quanterix and Akoya caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Neither Quanterix nor Akoya assumes any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
Business Wire
29-04-2025
- Business
- Business Wire
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9 million fewer shares than under the original deal terms. Quanterix shareholders will own approximately 84% of the combined company and Akoya shareholders will own approximately 16%. Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said, 'The strategic merits of the transaction remain strong even as the market has been focused on academic funding and tariff concerns. In light of recent volatility, we re-engaged with Akoya to revise the terms of the agreement. The combined company will provide a significant value creation opportunity for shareholders.' Brian McKelligon, Chief Executive Officer of Akoya, said, 'We remain excited to combine with Quanterix and believe this partnership offers compelling value for Akoya shareholders. We look forward to closing the transaction and leveraging our collective scale to drive synergies across our organizations and customers, expediting our path to profitability." Additional Details about the Transaction The revised transaction terms and amended merger agreement have been approved by the Quanterix Board and the Akoya Board, respectively. Shareholders of Akoya who hold more than 50% of Akoya's common stock have agreed to vote in favor of the merger on the amended terms. As a result of the amended merger agreement, Quanterix will no longer hold its previously announced special meeting of shareholders. The transaction is expected to close during the second quarter of 2025, subject to the approval of Akoya shareholders and satisfaction of other customary closing conditions. An updated investor presentation is being furnished by Quanterix to the Securities and Exchange Commission and also is available at highlighting the benefits of the combination. Advisors Goldman Sachs & Co. LLC is serving as financial advisor to Quanterix with Covington & Burling LLP and Sidley Austin LLP serving as legal counsel. Perella Weinberg Partners LP is serving as financial advisor to Akoya and DLA Piper LLP is serving as legal counsel. About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,200 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at About Akoya Biosciences As The Spatial Biology Company®, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit Important Additional Information In connection with the proposed acquisition of Akoya by Quanterix, Quanterix will file with the Securities and Exchange Commission (the 'SEC') a post-effective amendment to its registration statement on Form S-4 (as so amended, the 'Registration Statement'), which will contain a preliminary proxy statement of Akoya and a preliminary prospectus of Quanterix (the 'Proxy Statement/Prospectus'), and each of Quanterix and Akoya have, and may in the future, file with the SEC other relevant documents regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT QUANTERIX, AKOYA AND THE PROPOSED TRANSACTION. A definitive copy of the Proxy Statement/Prospectus will be mailed to Akoya stockholders when that document is final. Investors and security holders will be able to obtain the Registration Statement and the Proxy Statement/Prospectus, as well as other filings containing information about Quanterix and Akoya, free of charge from Quanterix or Akoya or from the SEC's website when they are filed. The documents filed by Quanterix with the SEC may be obtained free of charge at Quanterix's website, at or by requesting them by mail at Quanterix Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821. The documents filed by Akoya with the SEC may be obtained free of charge at Akoya's website, at or by requesting them by mail at Akoya Biosciences, Inc., 100 Campus Drive, 6th Floor, Marlborough, MA 01752 ATTN: Chief Legal Officer. Participants in the Solicitation Quanterix and Akoya and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Akoya in respect of the proposed transaction. Information about Akoya's directors and executive officers is available in the Proxy Statement/Prospectus and Akoya's proxy statement dated April 23, 2024, for its 2024 Annual Meeting of Stockholders, and other documents filed by Akoya with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Investors should read the definitive Proxy Statement/Prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Quanterix or Akoya as indicated above. No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the transaction contemplated by the Merger Agreement (the 'Merger'), nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Cautionary Statement Regarding Forward-Looking Statements Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on, among other things, projections as to the anticipated benefits of the Merger as well as statements regarding the impact of the Merger on Quanterix's and Akoya's business and future financial and operating results, the amount and timing of synergies from the Merger and the closing date for the Merger. Words and phrases such as 'may,' 'approximately,' 'continue,' 'should,' 'expects,' 'projects,' 'anticipates,' 'is likely,' 'look ahead,' 'look forward,' 'believes,' 'will,' 'intends,' 'estimates,' 'strategy,' 'plan,' 'could,' 'potential,' 'possible' and variations of such words and similar expressions are intended to identify such forward-looking statements. Quanterix and Akoya caution readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the Merger Agreement; the outcome of any legal proceedings that may be instituted against Quanterix or Akoya; the failure to obtain approval of Akoya's stockholders or to satisfy any of the other conditions to the Merger on a timely basis or at all; the possibility that the anticipated benefits and synergies of the Merger are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business; the possibility that the Merger may be more expensive to complete than anticipated; diversion of management's attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger; changes in Quanterix's share price before the closing of the Merger; risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the Merger; the ability of Akoya to repay any Convertible Notes and other factors that may affect future results of Quanterix, Akoya and the combined company. Additional factors that could cause results to differ materially from those described above can be found in the Proxy Statement/Prospectus, and in other documents Quanterix and Akoya file with the SEC, which are available on the SEC's website at All forward-looking statements, expressed or implied, included in this Current Report are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix's or Akoya's underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix and Akoya anticipate. Quanterix and Akoya caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Neither Quanterix nor Akoya assumes any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
Yahoo
01-04-2025
- Health
- Yahoo
Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
Simoa® technology highlighted in more than 80 posters and oral presentations demonstrating its impact on neurodegenerative disease research BILLERICA, Mass., April 01, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood spot extraction (DBS) kit as part of their industry-leading Simoa® assay kits at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria. This new extraction kit enables researchers to measure low-concentration biomarkers from dried blood spots using a more cost-effective and less invasive method. Current Alzheimer's and neurodegenerative disease tests often require complex sample handling, repeated collections, and offer limited accessibility, particularly in remote or resource-limited settings, due to their reliance on venous blood draws. To address this, Quanterix, leveraging research from its collaboration with the DROP-AD Project at the University of Gothenburg, has developed a downstream DBS extraction kit that includes buffers and a sample preparation protocol, enabling accurate and sensitive measurement of neuro biomarkers from a DBS matrix. Validation studies show that DBS samples from two different devices tested with Simoa ALZpath p-Tau 217 and the Simoa extraction kit demonstrated correlation to venous in simulated CSF spiked samples of 0.75 to 0.86. This advancement lays critical groundwork for the development of scalable, minimally invasive diagnostic tools that can be deployed more broadly and equitably across populations. "Our new dried blood spot (DBS) extraction kit represents a major step forward in making biomarker testing more accessible," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "By simplifying sample collection, DBS has the potential to expand participation in Alzheimer's research and clinical trials—especially among under-represented populations. This advancement will deepen our ability to understand the disease and its progression across diverse communities." Additionally, Quanterix's Simoa platform will be featured in over 80 posters, presentations, and sessions at AD/PD, demonstrating its significant role in advancing neurodegenerative disease research. For a full list of research available at AD/PD, please visit AD/PD's event website. About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,200 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at View source version on Contacts Media Contact:Marissa Klaassen(978) 488-1854media@ Investor Relations Contact:Joshua Young(508) 846-3327ir@
